Although most studies have focused on the role of NAT1 and NAT2 genetic polymorphisms in COAD risk, the potential role played by their aberrant expression in COAD has largely been ignored and whether NAT1 and NAT2 expression influences cancer patient survival remains unknown. This evidence concerns the gene NAT1 and cancer.